Selenium-coated nanostructured lipid carriers used for oral delivery of berberine to accomplish a synergic hypoglycemic effect

Juntao Yin,1 Yantao Hou,2 Yuyun Yin,3 Xiaoyong Song1 1Department of Pharmaceutics, Huaihe Hospital Affiliated to Henan University, 2Henan Vocational College of Applied Technology, Kaifeng, 3Henan Provincial Institute of Food and Drug Control, Zhengzhou, People’s Republic of China Abstrac...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Yin J, Hou Y, Yin Y, Song X
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://doaj.org/article/e72eab5360584e76b776654bb57f763b
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Juntao Yin,1 Yantao Hou,2 Yuyun Yin,3 Xiaoyong Song1 1Department of Pharmaceutics, Huaihe Hospital Affiliated to Henan University, 2Henan Vocational College of Applied Technology, Kaifeng, 3Henan Provincial Institute of Food and Drug Control, Zhengzhou, People’s Republic of China Abstract: Diabetes mellitus is an incurable metabolic disorder that seriously threatens human health. At present, there is no effective medication available to defeat it. This work intended to develop selenium-coated nanostructured lipid carriers (SeNLCs) for enhancing the oral bioavailability and the curative effect of berberine, an antidiabetic phytomedicine. Berberine-loaded SeNLCs (BB-SeNLCs) were prepared by hot-melt dispersion/homogenization procedure followed by in situ reduction. BB-SeNLCs were characterized by particle size, morphology, entrapment efficiency (EE) and in vitro release. Pharmacokinetics of berberine solution, berberine-loaded NLCs (BB-NLCs) and BB-SeNLCs were studied in Sprague Dawley rats administered by oral gavage. The prepared BB-SeNLCs were around 160 nm in particle size with an EE of 90%. In addition, BB-SeNLCs exhibited a better sustained release of berberine compared to the plain NLCs. After oral administration, BB-SeNLCs greatly enhanced the oral bioavailability of berberine, which was approximately 6.63 times as much as that of berberine solution. The hypoglycemic effect of BB-SeNLCs was also significantly superior to that of BB-NLCs and berberine solution. It turned out that sustained drug release and good intestinal absorption, plus the synergy of selenium, were basically responsible for enhanced oral bioavailability and hypoglycemic effect. Our findings show that SeNLCs are promising nanocarriers for oral delivery of berberine to strengthen the antidiabetic action. Keywords: berberine, diabetes mellitus, nanostructured lipid carriers, selenium, bioavailability